Smart Dividend Portfolio: Cash Capsule
1
Dear Investor,
Welcome to our weekly edition of TipRanks’ Smart Dividend Portfolio & Newsletter.
1
1
Market-Moving News: June 15, 2026
Stocks ended the week higher as investors looked past policy noise and leaned back into risk assets. The Dow Jones Industrial Average (DJIA) rose 0.70% to 51,202.26, while the S&P 500 (SPX) gained 0.50% to 7,431.46. The Nasdaq (NDX) climbed 0.64% to 29,635.95, helped by renewed interest in high-growth technology and space-related names.
The 10-year Treasury yield stood at 4.48%, while Gold (CM:XAUUSD) gained 3.18% to $4,235.10, and oil (CM:CL) fell 2.47% to $84.35. Bitcoin (BTC-USD) slipped 0.78% to $63,490.90 as crypto lagged the broader risk-on tone.
The week ahead will likely keep investors focused on the tenuous U.S.-Iran ceasefire, interest rates, AI policy, and whether the SpaceX IPO can continue to support risk appetite. Treasury yields remain high enough to pressure expensive growth stocks, but this week’s gains suggest investors are still willing to pay for companies with strong stories and clear market leadership.
AI remains a powerful theme, though the Anthropic restrictions show that the next phase may be shaped as much by government oversight as by product launches. Companies tied to cloud infrastructure, cybersecurity, and compute demand could stay in focus as investors weigh opportunity against regulation.
SpaceX (SPCX) dominated headlines last week with a blockbuster Nasdaq debut. Shares surged 19% on their first day of trading, valuing the company at more than $2 trillion and making its $75 billion IPO the largest in history. The listing also pushed founder Elon Musk’s net worth above $1.1 trillion, while early investors such as 137 Ventures stood to realize enormous gains. The event highlighted how successful private-market companies are becoming increasingly prominent in the public market.
Meanwhile, artificial intelligence remained in focus as the Trump administration reportedly restricted foreign access to advanced AI models developed by Anthropic. The move followed security concerns raised by Amazon (AMZN) researchers, who found ways to generate potentially harmful cybersecurity-related information despite existing safeguards. The administration’s decision underscores growing regulatory scrutiny of advanced AI, signaling that policymakers increasingly view cutting-edge AI systems as national security assets rather than purely commercial technologies. While AI’s long-term growth prospects remain strong, investors now face an additional layer of regulatory risk.
1
1
This Week’s Quality Dividend Stock Idea
Pfizer (PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines across a wide range of therapeutic areas, including oncology, immunology, cardiovascular disease, infectious diseases, and rare disorders. The company serves patients, healthcare providers, governments, and research institutions worldwide through a broad portfolio of innovative and established products. Pfizer is one of the world’s largest pharmaceutical companies, with a strong global presence, extensive research and development capabilities, and a diverse pipeline of potential new therapies.
1
Pharma Transformation
Pfizer’s history dates to 1849, when cousins Charles Pfizer and Charles Erhart founded a small chemicals business in Brooklyn, New York. Over the next century, the company evolved from a manufacturer of fine chemicals into a global pharmaceutical leader, driven by scientific innovation, expanding manufacturing capabilities, and a growing portfolio of prescription medicines. A major milestone came during World War II, when Pfizer developed large-scale penicillin production methods, helping establish its reputation as a leading pharmaceutical manufacturer.
In the decades that followed, Pfizer expanded through a combination of internal research, product innovation, and strategic acquisitions. The company built blockbuster franchises across cardiovascular disease, infectious diseases, inflammation, oncology, and vaccines, supported by successful products such as Lipitor, Viagra, and Prevnar. Acquisitions became an increasingly important growth driver. The purchases of Warner-Lambert in 2000 and Pharmacia in 2003 significantly expanded Pfizer’s product portfolio and global reach, while the acquisition of Wyeth in 2009 strengthened its vaccines, biologics, and consumer healthcare businesses.
That same year, Pfizer partnered with GSK to establish ViiV Healthcare, a company dedicated to HIV treatments. Initially, Pfizer held a 15% ownership stake, while GSK owned the remaining 85%. In 2012, Shionogi joined the venture after contributing its HIV portfolio in exchange for a 10% stake, reducing Pfizer’s ownership over time. ViiV became a leading player in HIV care, but as Pfizer increasingly focused on its core growth priorities, the investment became less strategic to the company’s long-term plans.
During the 2010s, management focused on improving operational efficiency, reshaping the portfolio, and increasing investment in innovative medicines. This transformation accelerated through a series of acquisitions designed to strengthen Pfizer’s position in high-growth therapeutic areas. In 2015, the company acquired Hospira, expanding its capabilities in sterile injectable medicines and biosimilars. The following year, Pfizer purchased Anacor Pharmaceuticals, adding innovative dermatology treatments, and acquired Medivation, gaining the blockbuster prostate cancer therapy Xtandi and significantly enhancing its oncology franchise.
Pfizer continued building its oncology platform in 2019 through the acquisition of Array BioPharma, which strengthened its targeted cancer therapy pipeline. At the same time, management streamlined the business by separating its off-patent medicines division, Upjohn, and merging it with Mylan in 2020 to create Viatris. The transaction allowed Pfizer to exit a slower-growing generics business and focus capital on higher-growth innovative medicines.
The company entered a new phase of expansion during the COVID-19 pandemic. In partnership with BioNTech, Pfizer developed Comirnaty, one of the world’s first mRNA COVID-19 vaccines, followed by the antiviral treatment Paxlovid. These products generated tens of billions of dollars in revenue, significantly boosting cash flow, strengthening the balance sheet, and further elevating its visibility worldwide.
Leveraging its enhanced financial position, Pfizer accelerated its acquisition strategy in 2022. The company acquired Arena Pharmaceuticals to expand its immunology pipeline, purchased Biohaven to gain the fast-growing migraine therapy Nurtec ODT, and acquired Global Blood Therapeutics, strengthening its rare disease and hematology portfolio. During the same period, Pfizer began exiting consumer health through the spin-off of Haleon, its consumer healthcare joint venture with GSK. The company gradually reduced its ownership stake and completed the sale of its remaining shares in 2025, fully exiting the consumer health business and sharpening its focus on innovative biopharmaceuticals.
The most transformational acquisition of recent years came in 2023, when Pfizer acquired Seagen. The deal established Pfizer as a leader in antibody-drug conjugates (ADCs), a rapidly growing class of targeted cancer therapies, and significantly expanded its oncology platform. In 2025, the company entered the obesity and cardiometabolic disease market through the acquisition of Metsera. The transaction added a portfolio of clinical-stage GLP-1 therapies, including injectable and oral candidates, positioning Pfizer to compete in one of healthcare’s fastest-growing markets.
As part of its broader portfolio optimization strategy, Pfizer also exited ViiV Healthcare earlier this year, selling its remaining 11.7% stake for approximately $1.9 billion. The divestiture generated additional capital to support debt reduction, business development, and investment in key growth areas such as oncology, vaccines, and obesity. The transaction reflected management’s ongoing effort to monetize non-core assets and concentrate resources on businesses where Pfizer has greater strategic control and long-term growth potential.
These acquisitions and divestitures reflect a consistent strategic approach: acquire externally validated science in attractive therapeutic categories, leverage Pfizer’s global development and commercialization capabilities to scale those assets and divest slower-growing businesses that no longer fit its long-term priorities. This strategy has transformed Pfizer into one of the world’s largest biopharmaceutical companies, with leadership positions in oncology, vaccines, immunology, rare diseases, and emerging cardiometabolic therapies, and supported by a diversified portfolio and multiple drivers of long-term earnings growth.
1
Growth Formula
Pfizer generates more than 95% of revenue through its Biopharma business, which markets innovative medicines and vaccines across oncology, internal medicine, immunology, rare diseases, inflammation, and hospital-based therapies. In addition to product sales, the company earns revenue from strategic alliances, co-commercialization agreements, royalties, and its Pfizer CentreOne contract development and manufacturing business.
The company’s business model is built around a portfolio of patented medicines and biologics that address large, often chronic, disease markets. Once a therapy receives regulatory approval, Pfizer leverages its global manufacturing network, commercial infrastructure, and relationships with healthcare providers, governments, hospitals, and insurers to distribute products at scale across more than 100 countries. This global reach allows successful therapies to generate revenue for many years while benefiting from operating leverage and strong cash generation.
Recent growth has been supported by strong demand for several key products, including the blood thinner Eliquis, the Prevnar vaccine franchise, the Vyndaqel portfolio for a rare heart disease, migraine treatment Nurtec, cancer therapy Padcev, and a growing portfolio of oncology medicines and biosimilars. Excluding COVID-related products, Pfizer’s revenue base from its recently launched and acquired productshas continued to expand, reflecting demand across multiple therapeutic categories.
A key pillar of Pfizer’s long-term growth strategy is continuous reinvestment in research and development, supplemented by acquisitions that add commercially validated products and late-stage pipeline assets. Recent acquisitions have expanded Pfizer’s presence in oncology, rare diseases, immunology, migraine treatments, and obesity therapies. These transactions provide new sources of future revenue while reducing dependence on any single product category.
At the same time, management has streamlined the company by exiting slower-growing consumer health and generic medicine businesses, allowing capital and resources to be concentrated on higher-margin innovative therapeutics. Combined with a deep development pipeline, global scale, strong intellectual property portfolio, and ongoing cost-efficiency initiatives, this business model provides multiple avenues for sustained revenue growth, earnings expansion, and long-term cash generation.
1
Innovation Arc
While investors have remained focused on looming loss-of-exclusivity risks, Pfizer’s underlying growth profile has improved meaningfully over the past several years. This shift is most evident in the performance of its recently launched and acquired products, which together have become an increasingly important driver of revenue growth and delivered strong operational gains in the latest quarter. This group includes products obtained through acquisitions such as Seagen, Biohaven, Arena Pharmaceuticals, and Global Blood Therapeutics, as well as internally developed therapies. Management views this portfolio as the primary bridge between today’s earnings base and the next phase of growth.
Oncology remains the company’s highest-priority growth area. The acquisition of Seagen has become the centerpiece of Pfizer’s cancer strategy, with Seagen products growing 20% operationally during the quarter. Management highlighted continued adoption across its antibody-drug conjugate (ADC) portfolio, a rapidly growing class of targeted cancer therapies. PADCEV was a particular standout, supported by clinical data showing that its combination with pembrolizumab reduced the risk of recurrence or death by nearly 50% in certain bladder cancer patients. Positive results could expand PADCEV into earlier stages of treatment and significantly increase its commercial opportunity.
Migraine treatment Nurtec, acquired through Biohaven, continues to be another important growth driver. Revenue increased 41% operationally in the quarter, supported by strong demand in both acute and preventive migraine treatment. Management noted that about 40% of physicians who prescribe traditional migraine therapies have not adopted oral CGRP medicines (small-molecule drugs) such as Nurtec, suggesting a substantial opportunity for continued market-share gains and physician adoption.
Another key area of focus is obesity, which management views as one of the largest pharmaceutical opportunities of the coming decade. Following the acquisition of Metsera, Pfizer is building a portfolio of next-generation obesity treatments designed to compete in a rapidly expanding market.
The company is targeting its first obesity approval in 2028 and is developing ultra-long-acting therapies that could potentially offer monthly maintenance dosing, creating differentiation from many currently marketed weekly injectable treatments. Management pointed to several upcoming catalysts, including data readouts from the VESPER clinical program and further updates on amylin-based obesity drug candidates, both of which are expected to be released later this year.
Pfizer is also starting to build a commercial presence in the obesity market through ecnoglutide, which was recently launched in China through its partnership with Sciwind Bioscience. Management highlighted encouraging clinical data showing about 15.1% weight loss at 48 weeks and expressed optimism about the opportunity, supported by China’s large population and rising obesity rates. Roughly 15% of the country’s population is classified as obese, representing a patient base larger than the total population of many developed countries.
Management described 2026 as one of the most important years in Pfizer’s recent R&D history. The company expects approximately 20 pivotal study initiations, eight major clinical data readouts, and four regulatory decisions. Roughly half of these key milestones are concentrated in oncology.
The company also highlighted artificial intelligence as a strategic priority across research, development, manufacturing, and commercial operations. Management believes AI can accelerate drug discovery, shorten development timelines, improve manufacturing efficiency, and enhance commercial execution, ultimately supporting productivity and long-term earnings growth.
Pfizer is advancing a broad pipeline of potential future revenue drivers across multiple high-value therapeutic areas. In oncology, the company is developing several experimental treatments targeting major cancers such as lung, prostate, breast, and blood cancers, including next-generation antibody- and targeted-therapy approaches. In addition, it is progressing with multiple late-stage programs designed to improve outcomes in multiple myeloma and other solid tumors.
Beyond cancer, Pfizer is also expanding in immunology and respiratory diseases with new therapies aimed at chronic inflammatory and airway conditions. At the same time, it continues to strengthen its vaccine franchise by developing next-generation vaccines, including updated candidates for pneumococcal disease.
Management emphasized that the pipeline should be viewed as a diversified portfolio rather than a series of binary outcomes. Instead of depending on a single blockbuster drug, Pfizer has multiple opportunities across oncology, obesity, vaccines, immunology, cardiovascular disease, and rare diseases.
1
Exclusivity Edge
Several developments have improved visibility into Pfizer’s future earnings and cash flow. A favorable Belgian court ruling1 regarding Comirnaty vaccine contracts with certain European governments strengthened Pfizer’s position in ongoing contractual disputes and may support future cash collections. Management also noted that recent declines in international COVID vaccine revenue were primarily attributable to the expiration of a large UK supply contract rather than a broad deterioration in vaccination demand. Pfizer continues to hold more than 60% market share in both U.S. and international COVID vaccine markets.
The company also resolved key uncertainty around Vyndamax, one of Pfizer’s largest and fastest-growing products for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), rare heart disease that primarily affects older adults. Like most pharmaceutical products, it operates under a patent-protected period before loss of exclusivity (LOE), when generic manufacturers can enter the market and sharply reduce sales and profits. The company had expected Vyndamax U.S. revenue to begin declining around 2029 due to generic competition. However, a recent settlement with three generic drug manufacturers extended exclusivity by approximately two and a half years, pushing potential entry to mid-2031.
The agreement reduces Pfizer’s projected LOE exposure from about $17 billion to roughly $14–15 billion, preserving billions in high-margin revenue. It also provides additional time for newer growth drivers – including oncology, obesity, rare disease, and migraine therapies – to scale before a larger patent cliff. The settlement also improves cash-flow visibility, providing management with greater flexibility around capital allocation, business development, and future shareholder returns.
Beyond organic growth, Pfizer still has about $7 billion in business development capacity, including proceeds from its ViiV Healthcare stake sale, but management indicated that a large, transformative acquisition is unlikely in the near term. The focus is instead on integrating recent deals, advancing AI-driven transformation efforts, and progressing the existing pipeline. The company remains open to smaller tuck-in acquisitions and licensing agreements in core areas such as oncology, obesity, immunology, vaccines, and rare diseases. The strategy prioritizes maximizing returns from prior acquisitions rather than pursuing another major merger.
Pfizer’s future growth story is increasingly being driven by a combination of rapidly growing launched products, a strengthening oncology franchise, a developing obesity platform, and one of the industry’s broadest pipelines. Combined with the Vyndamax settlement, which materially reduces patent-expiration risk, these factors underpin management’s confidence in a reacceleration of revenue growth beginning around 2029.
—
1-In April 2026, a Belgian court ruled in Pfizer’s favor in a dispute over COVID-19 vaccine supply contracts with certain EU countries, including Poland and Romania. The case stemmed from pandemic-era agreements that later became contentious as vaccine demand declined. While Pfizer did not disclose financial details, the ruling strengthens its legal position and improves the likelihood of collecting remaining revenue and cash tied to these contracts. The company is now coordinating with the affected governments to implement the judgment.
1
Booster Shot
Over the past five years, Pfizer has grown revenue and adjusted EPS at compound annual rates of 8.4% and 6.2%, respectively. However, those figures mask a highly unusual earnings cycle. The company’s results were first boosted by an unprecedented surge in demand for its COVID-19 products, Comirnaty and Paxlovid, before experiencing a sharp normalization as pandemic-related revenues declined. Since then, Pfizer has entered a stabilization phase, with growth increasingly driven by its core pharmaceutical portfolio and oncology assets acquired through the Seagen acquisition. While reported earnings have been weighed down by acquisition-related amortization, restructuring charges, and asset write-downs, the underlying business has remained profitable and cash-generative.
That underlying strength was evident in Pfizer’s latest quarterly results. The company delivered revenue of $14.5 billion, exceeding analyst expectations and growing 2% operationally year-over-year. Excluding COVID-related products, operational growth accelerated to approximately 7%, highlighting continued momentum across the core portfolio. Adjusted diluted EPS of $0.75 also exceeded expectations, while the adjusted operating margin reached 38%, remaining above pre-pandemic levels.
Growth was fueled by strong demand for several of Pfizer’s leading products, including its cancer medicines PADCEV and Lorbrena, the blockbuster anticoagulant Eliquis, migraine treatment Nurtec, and the Vyndaqel portfolio, which is used to treat a rare and increasingly diagnosed type of heart disease. Particularly encouraging was the performance of Pfizer’s recently launched and acquired products, which generated $3.1 billion in quarterly revenue and grew 22% operationally. On an annualized basis, these products now contribute more than $12 billion in revenue, providing evidence that the company’s business development strategy is helping offset future patent-expiration headwinds.
At the same time, Pfizer continued to balance growth investments with disciplined cost management. Adjusted selling, information, and administrative expenses declined 5% operationally due to productivity initiatives and more efficient commercial spending. Meanwhile, adjusted research and development expenses increased 11% as the company expanded investments in oncology and obesity, two of its most important long-term growth opportunities.
Profitability remained strong. Adjusted gross margin reached approximately 76% during the quarter, supported by a favorable product mix and ongoing cost-control efforts. Although higher royalty expenses created some pressure relative to the prior year, Pfizer’s manufacturing optimization initiatives continued to improve efficiency. Excluding Comirnaty, whose profits are shared equally with BioNTech, adjusted gross margins have consistently remained in the mid-to-upper-70% range in recent years. The company remains on track to achieve approximately $700 million in savings from the first phase of its manufacturing optimization program in 2026, with roughly $175 million already realized during the quarter.
Pfizer’s financial position also remains solid. Gross leverage stood at 2.7x at the end of the first quarter, while the company maintained investment-grade credit ratings of “A2” from Moody’s and “A” from S&P. Cash generation continued to improve, with free cash flow increasing 23% year-over-year to $2.18 billion, supported by a 12% increase in operating cash flow to $2.62 billion and disciplined capital spending.
Looking ahead, management remains confident in its cost-efficiency initiatives and expects to deliver the majority of its targeted $7.2 billion in net cost savings by the end of 2026. Reflecting confidence in the business, Pfizer reaffirmed its full-year 2026 guidance, maintaining its forecast for approximately $61 billion in revenue and adjusted EPS of $2.90 at the midpoint.
Beyond 2026, Pfizer’s strategy centers on investing in key growth assets while navigating patent expirations through 2028. Management expects the next phase of growth to be driven by its advancing R&D pipeline and the continued expansion of recently launched and acquired products. Following the Vyndamax settlement and a favorable Belgian court ruling related to Comirnaty, the company now has greater visibility into future revenues and cash flows. As a result, management believes Pfizer can achieve high-single-digit annual revenue growth beyond 2028, reinforcing its objective of delivering durable long-term growth and shareholder value creation.
1
Healthy Yield
Pfizer remains one of the pharmaceutical industry’s most established income investments. The company has paid dividends continuously since 1980 and has raised its payout for 16 consecutive years. Over the past decade, the dividend has grown at an annualized rate of 3.97%. Based on adjusted earnings, Pfizer distributes approximately 56.2% of its profits to shareholders, a level that appears sustainable while still allowing for investment in future growth. At current prices, the stock offers a dividend yield of 6.65%, over four times the healthcare sector average of 1.66%. Most recently, Pfizer declared a quarterly dividend of $0.43 per share.
Pfizer has $3.3 billion remaining under its share repurchase authorization but has paused buybacks since the Seagen acquisition as management prioritizes debt reduction, R&D investment, business development, and dividend growth. However, improved cash-flow visibility following the Vyndamax settlement and favorable legal rulings has made management more open to resuming repurchases in the future.
Although Pfizer’s shares have remained largely flat over the past year, the company has made meaningful progress in addressing many of the issues that previously weighed on investor sentiment. Debt reduction efforts are advancing, the outlook for key loss-of-exclusivity risks has improved following the Vyndamax settlement, and growth drivers in oncology and obesity are gaining traction. Combined with ongoing cost discipline, these developments suggest Pfizer is gradually moving beyond its post-COVID reset and positioning itself for renewed growth.
From a valuation perspective, Pfizer appears inexpensive. The stock trades at a modest discount to its historical averages based on non-GAAP trailing and forward P/E multiples and forward EV/EBITDA. Compared with large pharmaceutical peers such as Bristol Myers Squibb, Merck, Eli Lilly, and AstraZeneca, Pfizer trades toward the lower end of the valuation spectrum, based on non-GAAP trailing and forward P/E ratios and forward price-to-cash-flow multiples. The market continues to discount Pfizer for post-pandemic revenue normalization and future patent expirations, but this may underestimate the company’s growing oncology franchise, expanding obesity platform, improving loss-of-exclusivity outlook, and pipeline-driven growth potential later in the decade.
Analysts remain optimistic about PFE as the company’s investment outlook is supported by multiple positive late-stage and mid-stage clinical trial results have increased the likelihood of future approvals, while a stronger product mix and cost discipline have helped adjusted gross margins recover to the mid-70% range, supporting profitability and cash generation. Recently launched and acquired products are also delivering strong growth, demonstrating Pfizer’s ability to commercialize new therapies, diversify revenue streams, and offset future patent-expiration risks.
Reflecting these strengths, Wall Street’s consensus implies approximately 11% upside from current share levels, while more bullish estimates suggest potential gains of up to 37%. Discounted cash flow models point to even greater value, indicating that Pfizer shares may be trading at an approximately 58% discount to their estimated intrinsic value.
1
Investing Takeaway
For income investors, Pfizer offers a rare combination of an above-average dividend yield, a long history of dividend growth, and improving business fundamentals. While the market remains focused on the company’s post-pandemic revenue reset and future patent expirations, Pfizer continues to generate substantial cash flow, maintain investment-grade credit ratings, and prioritize its dividend as a core component of capital allocation. The company’s expanding oncology franchise, growing obesity platform, and deep pipeline provide potential avenues for future earnings growth, while ongoing cost reductions and improving cash-flow visibility support dividend sustainability. Although share repurchases remain secondary to debt reduction and business investment, management’s increasing confidence in the company’s financial position suggests greater flexibility over time. For investors seeking reliable income with the potential for long-term capital appreciation, Pfizer appears well-positioned to reward patient shareholders as its next generation of growth drivers comes to the fore.
1
1
Dividend Investor Portfolio
1
Portfolio News
▣ BlackRock’s (BLK) private credit business faced elevated redemption activity during the second quarter, prompting two of its funds to limit withdrawals after investor requests exceeded quarterly redemption caps. HPS Corporate Lending Fund received redemption requests equal to approximately 13.3% of shares outstanding, well above its 5% quarterly limit. As a result, the fund will repurchase about $620 million of shares. Despite the heightened withdrawal demand, management emphasized that portfolio performance remains strong, with underlying companies delivering 11% growth in both revenue and EBITDA over the past 12 months. The fund also maintained significant financial flexibility, including approximately $7.2 billion of available liquidity and leverage at the low end of its target range.
Similarly, BlackRock Private Credit Fund received redemption requests totaling about 5.3% of outstanding shares and will satisfy withdrawals up to its 5% cap, representing roughly $83 million. Management noted that the fund maintains modest leverage and approximately $1.4 billion of liquidity. In contrast, redemption requests at HPS Corporate Capital Solutions Fund remained below the 5% threshold, allowing all investor requests to be fulfilled. The developments highlight continued investor demand for liquidity in private credit funds, even as underlying portfolio performance remains resilient.
▣ Bank of Nova Scotia (BNS) has agreed to acquire Maple Financial Holdings, the parent company of MapleMark Bank, in a move that strengthens its U.S. presence and advances its North American growth strategy. A key benefit of the transaction is that it provides Scotiabank with access to Federal Deposit Insurance Corporation (FDIC) deposit insurance, an important advantage for expanding its U.S. deposit-gathering capabilities and supporting its mortgage capital markets business.
Management described MapleMark Bank as a well-managed institution with a strong presence in Dallas, Texas, a market that aligns with Scotiabank’s focus on growing its footprint along the North American trade and investment corridor. The acquisition is expected to enhance the bank’s strategic positioning in the United States without significantly increasing financial risk. Scotiabank noted that the transaction is not expected to have a material impact on either earnings or its Common Equity Tier 1 (CET1) capital ratio, indicating that the deal is primarily a strategic expansion initiative rather than a near-term financial catalyst.
▣ ExxonMobil (XOM) was at the center of two notable developments this week, highlighting both its global growth ambitions and the strength of its existing production portfolio. A Bloomberg report indicated that Exxon is evaluating the Australian LNG producer as a potential acquisition target. According to the report, Exxon has held early-stage internal discussions as it explores ways to expand its presence in liquefied natural gas and strengthen access to Asian energy markets. Woodside, Australia’s largest LNG exporter, has long-term supply agreements across key Asian markets and has become increasingly attractive as buyers seek alternatives to Middle Eastern energy supplies amid disruptions in the Strait of Hormuz.
Separately, Guyana’s government is reviewing Exxon’s request to increase production at its Yellowtail development by an additional 30,000 barrels per day. If approved, output from the Stabroek Block would rise to approximately 945,000 barrels per day. Exxon, which operates the consortium responsible for all of Guyana’s oil production, generated about $4.7 billion in profit from its Guyana operations in 2025, underscoring the country’s growing importance as one of the company’s most valuable long-term growth engines.
▣ Honeywell (HON) is sharpening its acquisition strategy as it prepares for the separation of its aerospace business and continues to streamline its portfolio. At the company’s investor day, management said it is targeting bolt-on acquisitions valued between $2 billion and $4 billion to expand its Industrial Automation segment, narrowing its previous preferred deal range of $1 billion to $7 billion.
The company’s management highlighted the significant consolidation opportunity in what Honeywell estimates is a fragmented $35 billion market. Management believes targeted acquisitions can strengthen the business’s technology capabilities and accelerate growth in attractive automation end markets.
Despite its appetite for dealmaking, Honeywell emphasized a disciplined capital allocation approach. CFO Mike Stepniak said the company will continue to prioritize debt reduction, organic investment, and shareholder returns before pursuing larger transactions. The strategy reflects Honeywell’s focus on building a more focused industrial automation platform while maintaining financial flexibility as it executes its broader portfolio transformation.
▣ Kroger (KR) is set to report fiscal first-quarter results on June 18, with investors focused on whether the grocery retailer can sustain its recent momentum in identical sales growth and profitability. Wall Street expects revenue of approximately $45.6 billion and EPS of about $1.59 for the quarter.
The company enters the quarter following a solid fourth-quarter performance, where adjusted EPS of $1.28 exceeded expectations and identical sales excluding fuel rose 2.4%. Management also projected fiscal 2026 adjusted EPS of $5.20 at the midpoint and identical sales growth excluding fuel of 1% to 2%.
Investors will be watching several key areas, including identical sales trends, pharmacy performance, digital sales growth, and progress toward improving e-commerce profitability.
1
Recent Trades
None at the moment, although we are considering adding a stock to our portfolio when the market conditions allow for an attractive entry point. Stay tuned.
1
1
Portfolio Attributes
| Dividend Portfolio Yield |
Expected Dividend Growth | Expected Annual Income |
| 3.93% | +5.92% | $6,164.34 |
| Yield-on-Cost Adjusted, Weighted |
Average Analyst 12-Month Growth Outlook | 10K Per Stock at the Time of Purchase |
1
Current Portfolio
| Name | EX-Dividend Date | Payment Date | Yield on Cost | Annual DPS |
| Automatic Data Processing (ADP) | Jun 15, 2026 | Jul 01, 2026 | 2.46% | $6.80 |
| Amgen (AMGN) | Aug 20, 2026 | Sep 10, 2026 | 3.27% | $10.08 |
| BlackRock (BLK) | Sep 03, 2026 | Sep 24, 2026 | 2.61% | $22.92 |
| Bank of Nova Scotia (BNS) | Jul 02, 2026 | Jul 29, 2026 | 5.98% | $3.21 |
| EOG Resources (EOG) | Jul 16, 2026 | Jul 30, 2026 | 3.06% | $4.08 |
| ExxonMobil (XOM) | Aug 13, 2026 | Sep 10, 2026 | 3.64% | $4.12 |
| Honeywell International (HON) | Aug 13, 2026 | Sep 03, 2026 | 2.39% | $4.76 |
| IBM (IBM) | Aug 06, 2026 | Sep 10, 2026 | 3.16% | $6.76 |
| JPMorgan Chase (JPM) | Jul 03, 2026 | Jul 31, 2026 | 3.43% | $6.00 |
| Kroger (KR) | Aug 13, 2026 | Sep 03, 2026 | 3.08% | $1.40 |
| Cisco Systems (CSCO) | Jul 02, 2026 | Jul 23, 2026 | 2.22% | $1.68 |
| PepsiCo (PEP) | Sep 03, 2026 | Sep 24, 2026 | 3.8% | $5.69 |
| Philip Morris (PM) | Jun 29, 2026 | Jul 15, 2026 | 6.06% | $5.88 |
| Qualcomm (QCOM) | Sep 03, 2026 | Sep 24, 2026 | 2.44% | $3.68 |
| VICI Properties (VICI) | Jun 18, 2026 | Jul 10, 2026 | 5.22% | $1.8 |
| Verizon (VZ) | Jul 09, 2026 | Aug 03, 2026 | 6.09% | $2.76 |
1
1
Click here for additional Newsletters from TipRanks’ Macro & Markets Research Analysis Team
1
Disclaimer
The information contained in this article represents the views and opinions of the writer only, and not the views or opinions of TipRanks or its affiliates and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy, or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment, and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices, or performance.
